China manufacturers produce Covid-19 vaccines and supply to different countries around the world. Here is a brief introduction for the top 3 Covid-19 Vaccine Manufacturers in China.
China National Biotec Group (CNBG)
- Headquarter:Beijing,China
- Time of Establishment:1989
- Employees:＞2000
- CNBG’s Covid-19 vaccine in China:
CNBG’s inactivated COVID-19 vaccine has been granted conditional registration by China NMPA on December 31, 2020.
- CNBG Covid-19 vaccine in the world:
Get approval or emergency use in countries including Bolivia , UAE and Bahrain, Argentina,Peru and so on.
- Company Introduction
CNBG is a is a subsidiary of SINOPHARM, which is the first manufacturer of vaccines and blood products in China. CNBG is with 6 Biological Products Institutes around China, devoting to the research, development, production and supply of biological products since 1919.
Sinovac Life Sciences Co., Ltd (Sinovac, NASDAQ:SVA)
- Headquarter:Beijing,China
- Time of Establishment:2001
- Employees:657
- Sinovac’s Covid-19 vaccine in China:
Sinovac get conditional marketing authorization in China for COVID-19 Vaccine
- Sinovac’s Covid-19 vaccine in the world:
CoronaVac is being used under emergency use approval (EUA) in Indonesia, Brazil, Turkey and Chile.
- Company Introduction
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac’s product portfolio includes vaccines against enterovirus71 (EV71), hepatitis A and B, seasonal influenza, 23-Valent Pneumococcal Polysaccharide (“PPV”), H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella vaccine and mumps.
CanSino Biologics Inc. (CanSinoBIO, SHSE: 688185, HKEX:06185)
- Headquarter: Tianjin, China
- Time of Establishment:2009
- Employees:＞600
- CanSino’s Covid-19 vaccine in China:
CanSino get conditional marketing of recombinant Covid vaccine by NMPA, Feb 24th,2021
- CanSino’s Covid-19 vaccine around the world:
CanSino’s Covid-19 vaccine launched Phase III Clinical Trial in Pakistan, Mexico, Russia, Chile and Argentina up to now.
- Company Introduction
CanSino Biologics Inc. is an innovative biopharmaceutical company dedicated to exploring best solutions to the prevention of diseases through cutting edge research & development, advanced manufacturing and commercialization of innovative vaccine products for human use worldwide.
